SII, DNDi partner for expanding human trials for dengue treatment
The collaboration will be instrumental in advancing clinical development of a dengue monoclonal antibody in Brazil and potentially other endemic countries in Southeast Asia, with a focus on making treatment affordable and accessible, SII Executive Director Dr. Prasad Kulkarni said…
Read More
0
